333 related articles for article (PubMed ID: 25512109)
41. Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer.
Chen DR; Lu DY; Lin HY; Yeh WL
Biomed Res Int; 2014; 2014():532161. PubMed ID: 25140317
[TBL] [Abstract][Full Text] [Related]
42. Extracellular high mobility group box chromosomal protein 1 promotes drug resistance by increasing the expression of P‑glycoprotein expression in gastric adenocarcinoma cells.
Yin Y; Li W; Deng M; Zhang P; Shen Q; Wang G; Tao K
Mol Med Rep; 2014 Apr; 9(4):1439-43. PubMed ID: 24549588
[TBL] [Abstract][Full Text] [Related]
43. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
44. Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases.
de la Torre M; Hao XY; Larsson R; Nygren P; Tsuruo T; Mannervik B; Bergh J
Anticancer Res; 1993; 13(5A):1425-30. PubMed ID: 7902062
[TBL] [Abstract][Full Text] [Related]
45. HMGB1-induced autophagy promotes chemotherapy resistance in leukemia cells.
Liu L; Yang M; Kang R; Wang Z; Zhao Y; Yu Y; Xie M; Yin X; Livesey KM; Lotze MT; Tang D; Cao L
Leukemia; 2011 Jan; 25(1):23-31. PubMed ID: 20927132
[TBL] [Abstract][Full Text] [Related]
46. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
47. Umbilical cord-derived mesenchymal stem cells promote proliferation and migration in MCF-7 and MDA-MB-231 breast cancer cells through activation of the ERK pathway.
Li T; Zhang C; Ding Y; Zhai W; Liu K; Bu F; Tu T; Sun L; Zhu W; Zhou F; Qi W; Hu J; Chen H; Sun X
Oncol Rep; 2015 Sep; 34(3):1469-77. PubMed ID: 26151310
[TBL] [Abstract][Full Text] [Related]
48. High Mobility Group Box1 (HMGB1) released from cancer cells induces the expression of pro-inflammatory cytokines in peritoneal fibroblasts.
Abe A; Kuwata T; Yamauchi C; Higuchi Y; Ochiai A
Pathol Int; 2014 Jun; 64(6):267-75. PubMed ID: 24965109
[TBL] [Abstract][Full Text] [Related]
49. Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox.
Yao L; Zhang Y; Chen K; Hu X; Xu LX
PLoS One; 2011; 6(9):e24684. PubMed ID: 21931812
[TBL] [Abstract][Full Text] [Related]
50. Autophagy induction contributes to the resistance to methotrexate treatment in rheumatoid arthritis fibroblast-like synovial cells through high mobility group box chromosomal protein 1.
Xu K; Cai YS; Lu SM; Li XL; Liu L; Li Z; Liu H; Xu P
Arthritis Res Ther; 2015 Dec; 17():374. PubMed ID: 26702616
[TBL] [Abstract][Full Text] [Related]
51. HMGB1 promotes drug resistance in osteosarcoma.
Huang J; Ni J; Liu K; Yu Y; Xie M; Kang R; Vernon P; Cao L; Tang D
Cancer Res; 2012 Jan; 72(1):230-8. PubMed ID: 22102692
[TBL] [Abstract][Full Text] [Related]
52. [Autophagy is involved in doxorubicin induced resistance of human myeloma cell line RPMI8226].
Pan YZ; Wang X; Bai H; Wang CB; Zhang Q; Xi R
Zhonghua Xue Ye Xue Za Zhi; 2013 Jun; 34(6):489-92. PubMed ID: 23827103
[TBL] [Abstract][Full Text] [Related]
53. MiR-142-3p enhances chemosensitivity of breast cancer cells and inhibits autophagy by targeting HMGB1.
Liang L; Fu J; Wang S; Cen H; Zhang L; Mandukhail SR; Du L; Wu Q; Zhang P; Yu X
Acta Pharm Sin B; 2020 Jun; 10(6):1036-1046. PubMed ID: 32642410
[TBL] [Abstract][Full Text] [Related]
54. [Influence of HMGB1/MAPK/m-TOR signaling pathway on cell autophagy and chemotherapy resistance in K562 cells].
Liu L; Gao F; Ye Y; Chen Z; Dai Y; Zhao P; Guan G; Zhao M
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Oct; 41(10):1016-1023. PubMed ID: 27807322
[TBL] [Abstract][Full Text] [Related]
55. Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.
Guin S; Ma Q; Padhye S; Zhou YQ; Yao HP; Wang MH
Cancer Chemother Pharmacol; 2011 May; 67(5):1073-83. PubMed ID: 20658288
[TBL] [Abstract][Full Text] [Related]
56. Basic fibroblast growth factor promotes doxorubicin resistance in chondrosarcoma cells by affecting XRCC5 expression.
Hsieh MJ; Huang C; Lin CC; Tang CH; Lin CY; Lee IN; Huang HC; Chen JC
Mol Carcinog; 2020 Mar; 59(3):293-303. PubMed ID: 31916307
[TBL] [Abstract][Full Text] [Related]
57. Synergistic anti-cancer effects of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma cells.
Sharma G; Tyagi AK; Singh RP; Chan DC; Agarwal R
Breast Cancer Res Treat; 2004 May; 85(1):1-12. PubMed ID: 15039593
[TBL] [Abstract][Full Text] [Related]
58. Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity.
Bamodu OA; Huang WC; Tzeng DT; Wu A; Wang LS; Yeh CT; Chao TY
Cancer Lett; 2015 Aug; 364(2):125-34. PubMed ID: 25976769
[TBL] [Abstract][Full Text] [Related]
59. Intratumoral expression of mature human neutrophil peptide-1 potentiates the therapeutic effect of doxorubicin in a mouse 4T1 breast cancer model.
Li D; Qin Q; Wang XY; Shi HS; Luo M; Guo FC; Wang W; Wang YS
Oncol Rep; 2014 Mar; 31(3):1287-95. PubMed ID: 24378474
[TBL] [Abstract][Full Text] [Related]
60. Paclitaxel-doxorubicin sequence is more effective in breast cancer cells with heat shock protein 27 overexpression.
Shi P; Wang MM; Jiang LY; Liu HT; Sun JZ
Chin Med J (Engl); 2008 Oct; 121(20):1975-9. PubMed ID: 19080259
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
